Bullish indicating open at $55-$60, IPO prices at $37
National Research Corporation (NASDAQ:NRC), a Delaware-incorporated company specializing in commercial physical and biological research with a market capitalization of $296 million, has disclosed significant corporate updates in a recent 8-K filing with the Securities and Exchange Commission (SEC). According to InvestingPro analysis, the company appears undervalued based on its Fair Value assessment. The report, dated May 7, 2025, outlines the results of the company’s Annual Meeting held on the same date.
The shareholders approved the National Research Corporation 2025 Omnibus Incentive Plan, effective immediately. This plan supersedes the 2006 Equity Incentive Plan and the 2004 Non-Employee Director Stock Plan. The company maintains strong shareholder returns with a 3.7% dividend yield and management’s active share buyback program, as highlighted in InvestingPro’s analysis. Detailed information about the 2025 Omnibus Incentive Plan was previously provided in the proxy statement filed on April 10, 2025.
Additionally, the Annual Meeting saw the election of Donald M. Berwick and Stephen H. Lockhart as directors, both set to serve three-year terms expiring at the 2028 annual meeting of shareholders. The election results were overwhelmingly positive, with both candidates receiving substantial support from the voting shareholders.
Another key decision ratified at the meeting was the appointment of KPMG LLP as the company’s independent registered public accounting firm for 2025.
Furthermore, the compensation of the company’s named executive officers, as detailed in the proxy statement, received advisory approval from the shareholders.
The 8-K filing not only communicates these updates to the SEC but also serves as a transparent record for current and potential investors, providing insights into the company’s governance practices and strategic direction. The full text of the 2025 Omnibus Incentive Plan is included as an appendix in the proxy statement, offering stakeholders the opportunity to review the plan’s specifics.
National Research Corporation, headquartered in Lincoln, Nebraska, continues to adhere to strict corporate governance standards, as evidenced by the recent shareholder decisions. The company maintains a "GOOD" overall financial health score according to InvestingPro, with robust profitability metrics including a 60.3% gross profit margin and an 18.9% return on assets. The company’s executive team, led by CEO Michael D. Hays (LON:HAYS), remains committed to driving growth and innovation within the research industry, despite facing a challenging year with a revenue decline of 4.2% in the last twelve months.
In other recent news, National Research Corporation has announced several key developments. The company disclosed changes in its executive team, appointing Michael D. Hays as the principal financial officer while he continues as CEO until Trent (NSE:TREN) Green takes over on June 1, 2025. Additionally, Jordan N. Freeman has been named the new Chief Accounting Officer, bringing extensive accounting and finance experience to the role. In a separate announcement, NRC Health revealed adjustments to its executive compensation structure, introducing significant stock grants and modified cash bonuses for certain officers, excluding the current and future CEOs. Notably, Helen L. Hrdy, the Chief Operating Officer, received a grant of 100,000 shares of common stock with specific conditions and a cash bonus tied to the stock’s value.
Furthermore, National Research Corporation declared a quarterly cash dividend of $0.12 per share, payable to shareholders of record by March 28, 2025. This decision underscores the company’s commitment to returning value to its shareholders and confidence in its financial stability. The board’s actions reflect a strategic direction aimed at aligning executive interests with those of shareholders and positioning the company for future growth. These developments are based on the latest filings and press releases from National Research Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.